{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:59:15Z","timestamp":1787169555648,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>In recent years, there is an increasing interest in the use of linezolid for the treatment of tuberculosis (TB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients less than 18 years of age who received linezolid within the Spanish Pediatric TB Network from 2001 to 2016 were retrospectively included. Treatment characteristics, adverse events (AEs) and outcomes were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifteen children were included (53% male) with a median age of 3.6 years [interquartile range (IQR): 1.6\u20136.2]. Median follow-up was 54 months (IQR: 38\u201376). The reasons for linezolid use were drug-resistant TB in 8 (53%) patients, drug-induced liver injury in 5 (33%) patients and chronic liver disease in 2 (13%) patients. Four children (26%) were on immunosuppressive therapy when TB was diagnosed. Five children (33%) were diagnosed with extrapulmonary TB. The median duration of linezolid treatment was 13 months (IQR: 7.5\u201317). Nine patients had 13 linezolid-related AEs. Hematologic toxicity was observed in 8 patients (53%) and gastrointestinal intolerance in 3 patients (20%). In 2 patients, linezolid dose was reduced, and in 2 patients, linezolid was discontinued because of AEs. A 2-year-old girl went back to her country of birth and was lost to follow-up. No relapses were observed among the other 14 patients (93%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Linezolid may be considered when treating children with drug-resistant TB but also in the cases of patients with chronic liver disease or drug-induced liver injury. However, AEs should be closely monitored. Further studies are needed to determine the optimum dosage and the optimal duration of linezolid treatment in children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000002093","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T15:52:56Z","timestamp":1526053976000},"page":"263-267","source":"Crossref","is-referenced-by-count":18,"title":["Linezolid-containing Treatment Regimens for Tuberculosis in Children"],"prefix":"10.1097","volume":"38","author":[{"given":"Luis M.","family":"Prieto","sequence":"first","affiliation":[{"name":"Paediatric Infectious Diseases Unit, Department of Paediatrics, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Santiago","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Unit, Department of Paediatrics, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"del Rosal","sequence":"additional","affiliation":[{"name":"Tropical and Infectious Diseases Unit, Department of Paediatrics, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Carazo","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases and Immunodeficiencies Unit, Department of Paediatrics, Hospital Regional Universitario de M\u00e1laga, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"P\u00e9rez-Gorricho","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Unit, Department of Paediatrics, Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Rubio","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Hospital Nuestra Se\u00f1ora de Sonsoles, \u00c1vila, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Tagarro","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Hospital Universitario Infanta Sof\u00eda, San Sebasti\u00e1n de los Reyes, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bl\u00e1zquez-Gamero","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Unit, Department of Paediatrics, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Moreno-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases and Immunodeficiencies Unit, Department of Paediatrics, Hospital Regional Universitario de M\u00e1laga, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J.","family":"Mellado","sequence":"additional","affiliation":[{"name":"Tropical and Infectious Diseases Unit, Department of Paediatrics, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Baquero-Artigao","sequence":"additional","affiliation":[{"name":"Tropical and Infectious Diseases Unit, Department of Paediatrics, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tube.2013.10.003","article-title":"Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations.","volume":"94","author":"Garcia-Prats","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/AAC.42.12.3251","article-title":"The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria.","volume":"42","author":"Swaney","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijantimicag.2006.02.011","article-title":"In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates.","volume":"28","author":"Tato","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0140-6736(14)60195-1","article-title":"Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates.","volume":"383","author":"Jenkins","year":"2014","journal-title":"Lancet"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(16)30132-3","article-title":"Global burden of drug-resistant tuberculosis in children: a mathematical modelling study.","volume":"16","author":"Dodd","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/INF.0000000000000111","article-title":"Pediatric drug-resistant tuberculosis in Madrid: family matters.","volume":"33","author":"Santiago","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1473-3099(12)70033-6","article-title":"Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis.","volume":"12","author":"Ettehad","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/648675","article-title":"Linezolid in the treatment of multidrug-resistant tuberculosis.","volume":"50","author":"Schecter","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.","volume":"15","author":"Agyeman","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/INF.0000000000001270","article-title":"Pediatric extrapulmonary tuberculosis: clinical spectrum, risk factors and diagnostic challenges in a low prevalence region.","volume":"35","author":"Santiago-Garc\u00eda","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"9 suppl","key":"R15-20230912","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1097\/01.inf.0000087022.58089.d8","article-title":"Safety and tolerability of linezolid in children.","volume":"22","author":"Saiman","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jpids\/pit012","article-title":"Consensus statement on research definitions for drug-resistant tuberculosis in children.","volume":"2","author":"Seddon","year":"2013","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00007890-200001150-00013","article-title":"Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens.","volume":"69","author":"Meyers","year":"2000","journal-title":"Transplantation"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1086\/597590","article-title":"Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology.","volume":"48","author":"Aguado","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy.","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl 4","key":"R20-20230912","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1469-0691.2001.00061.x","article-title":"Linezolid: pharmacokinetic characteristics and clinical studies.","volume":"7","author":"Bouza","year":"2001","journal-title":"Clin Microbiol Infect"},{"issue":"suppl 4","key":"R21-20230912","first-page":"iv3","article-title":"Linezolid: safety and efficacy in special populations.","volume":"66","author":"Gould","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jpids\/piu035","article-title":"Linezolid-associated thrombocytopenia in children with renal impairment.","volume":"4","author":"Jones","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10156-010-0188-8","article-title":"Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery.","volume":"17","author":"Ikuta","year":"2011","journal-title":"J Infect Chemother"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1399-3062.2011.00617.x","article-title":"Efficacy and safety of linezolid in liver transplant patients.","volume":"13","author":"Radunz","year":"2011","journal-title":"Transpl Infect Dis"},{"issue":"suppl 3","key":"R25-20230912","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1093\/cid\/ciw483","article-title":"Optimal clinical doses of faropenem, linezolid, and moxifloxacin in children with disseminated tuberculosis: goldilocks.","volume":"63","author":"Srivastava","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1164\/rccm.201606-1227CI","article-title":"New and repurposed drugs for pediatric multidrug-resistant tuberculosis. practice-based recommendations.","volume":"195","author":"Harausz","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"e00751","DOI":"10.1128\/AAC.00751-17","article-title":"Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis.","volume":"61","author":"Srivastava","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"R28-20230912","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","article-title":"Linezolid: a review of safety and tolerability.","volume":"59","author":"Vinh","year":"2009","journal-title":"J Infect"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clinthera.2010.01.019","article-title":"Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review.","volume":"32","author":"Chiappini","year":"2010","journal-title":"Clin Ther"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"e1528","DOI":"10.1542\/peds.2010-2125","article-title":"Linezolid-associated peripheral and optic neuropathy in children.","volume":"127","author":"Nambiar","year":"2011","journal-title":"Pediatrics"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1128\/AAC.01179-10","article-title":"Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.","volume":"55","author":"Wallis","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201903000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T18:28:30Z","timestamp":1694543310000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201903000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002093","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733218612.793547522","asserted-by":"object"}]},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}